Welcome to our dedicated page for Arch Therapeutics news (Ticker: ARTH), a resource for investors and traders seeking the latest updates and insights on Arch Therapeutics stock.
Arch Therapeutics, Inc. (ARTH) is a biotechnology innovator developing advanced wound care solutions through its proprietary AC5 self-assembling technology platform. This resource provides comprehensive coverage of the company's latest developments, financial updates, and regulatory milestones.
Investors and industry professionals will find timely updates on product advancements, clinical trial progress, and strategic partnerships. Our curated news collection includes earnings reports, management commentary, and analysis of technological breakthroughs in hemostasis and wound management.
Key areas of coverage include regulatory submissions for AC5-based medical devices, peer-reviewed research publications, and corporate developments impacting ARTH's market position. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Arch Therapeutics' official communications and third-party analysis. Check back regularly for updates on the company's progress in commercializing next-generation surgical and trauma care solutions.
Arch Therapeutics (OTCQB: ARTH) will showcase its AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall) in Las Vegas from October 2-5, 2024. The company aims to educate clinicians about AC5, present case studies, and continue strategic meetings with wound care companies.
AC5 is a self-assembling wound care product cleared by the FDA for managing partial and full-thickness wounds. Two clinical cases demonstrating AC5's effectiveness will be presented during the poster viewing session on October 4, 2024:
- Management of tunneling wounds using synthetic self-assembling peptide matrix
- A pilot study on lower extremity wounds utilizing a novel nanoparticle self-assembling peptide
Arch Therapeutics' CEO, Terrence W. Norchi, MD, highlighted AC5's potential importance in addressing the needs of over 6 million people with non-healing wounds in the US alone.
Arch Therapeutics, Inc. will showcase its AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting. The clinical case featuring the use of AC5 in patients with lower extremity wounds will be presented during the event. AC5 is a FDA-cleared product for managing partial and full-thickness wounds, offering unique technology for wound care.
Arch Therapeutics announced the exhibition of its AC5® Advanced Wound System at the Symposium on Advanced Wound Care (SAWC) Spring 2023, held from April 26-30 in National Harbor, MD. This conference marks Arch's first opportunity to present AC5 since the Centers for Medicare and Medicaid Services (CMS) established a dedicated reimbursement code, A2020, effective April 1, 2023.
During SAWC, the company will showcase the product's efficacy and introduce clinicians to its innovative self-assembling technology. Notably, two case studies demonstrating AC5's clinical success will be presented. Arch's President, Terrence W. Norchi, emphasized the significance of presenting AC5 alongside the new reimbursement code, reiterating its potential to improve patient outcomes while reducing healthcare costs.
Arch Therapeutics (OTCQB: ARTH) announced a new HCPCS code A2020 for its AC5® Advanced Wound System, effective April 1, 2023. This code is expected to enhance reimbursement opportunities for AC5 in outpatient settings, facilitating increased adoption among healthcare providers.
According to VP of Sales, Dan Yrigoyen, the new code has already sparked inquiries from potential customers previously hesitant to order AC5. The AC5 system, cleared by the FDA, is designed for managing various wound types, with case studies indicating improved patient outcomes. The code signifies a key milestone in Arch's commercialization strategy, aiding in the pursuit of better wound healing solutions.
Arch Therapeutics, Inc. (OTCQB: ARTH) announced a significant milestone with the establishment of a new Level II HCPCS code, A2020, by the Centers for Medicare and Medicaid Services (CMS) for its AC5® Advanced Wound System. Effective April 1, 2023, this code aims to facilitate reimbursement processes, enhancing the accessibility of AC5 in various healthcare settings, including doctors' offices and wound care clinics. CEO Terrence Norchi expressed optimism that this development will improve clinician access to AC5 and support revenue growth by allowing they engage directly with payors for favorable payment policies.
Arch Therapeutics (OTCQB: ARTH) announced an expansion of its contracted sales force to enhance the commercialization of its AC5® Advanced Wound System. By the end of Q1 2023, approximately 15 independent commission-based sales representatives will be added to support sales in government facilities, including the Department of Veterans Affairs, Indian Health Services, and the Department of Defense. This strategy aims to optimize sales in regions with initial orders for AC5. Positive data from early use in challenging cases has been presented at recent conferences, reinforcing the product's potential in acute and chronic wound management.
